Medication effectiveness concerns
Food and Drug Administration and has been shown to suppress appetite, leading people to lose weight, said Dr
At the time of this writing, no peer-reviewed human studies demonstrate weight loss or metabolic benefits
Specifically: North Dakota updated its essential health benefit (EHB) benchmark plan under the Affordable Care Act to require, beginning in 2025 , prescription drug coverage of GLP-1s and GIPs as therapy for prevention of diabetes and treatment of insulin resistance, metabolic syndrome or morbid obesity
KLOW is supplied strictly for laboratory research use
However, complete recovery, especially of neurological symptoms, may take up to 6-12 months